Appendix cancer secondary prevention

Jump to navigation Jump to search

Appendix cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Differentiating Appendix cancer from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

MRI

CT scan

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Appendix cancer secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Appendix cancer secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Appendix cancer secondary prevention

CDC on Appendix cancer secondary prevention

Appendix cancer secondary prevention in the news

Blogs on Appendix cancer secondary prevention

Directions to Hospitals Treating Appendix cancer

Risk calculators and risk factors for Appendix cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

There are neither evidence based guidelines nor RCTs for follow up of appendix carcinoid tumors. Meanwhile, consensus based effective measures for the secondary prevention of appendix cancer include follow up history and physical examination, tumor marker measurements like CEA, CA-125, CA 19-9, follow up imaging studies, carcinoid tumor markers such serotonin, and specific imaging studies such as octreotide scintigraphy.

Secondary Prevention

Effective measures for the secondary prevention of appendix cancer include:

  • National Comprehensive Cancer Network (NCCN) and North American Neuroendocrine Tumor Society (NANETS) recommendations are based on the tumor size:[1]
  • Less than 2 cm: No follow up
  • NANETS devided tumors < 2 cm into two categories:
  • Tumors less than 1 cm needs no further follow up
  • Tumors between 1 and 2 cm with nodal metastasis, vascular invasion, lymphatic metastasis, mesoappendical invasion, intermediate and high grade as well as mixed histology: The same as tumors larger than 2 cm
  • Two cm and more: History and physical examination between 3-12 months plus tumor markers as well as imaging studies consideration for the first year, then tumor markers every 6-12 months (5-HIAA and chromogranin-A), imaging as clinically indicated.
  • Followup imaging studies: 6 month after surgery, every 6-12 month for at least 7 years.


  • Adenocarcinoma
  • There are no appropriate evidences in role of tumor markers for follow up of the patients with appendix adenocarcinoma, indeed current consensus is based on colorectal cancer experience.
  • CEA, CA-125, CA 19-9 every 6 month for the first two years, then yearly for at least 3 more years, plus continued follow up in selected cases.
  • Follow up Imaging studies: 6 moth after surgery, every 6-12 months for at least 7 years.

References

Template:WH Template:WS